Home | GvHD Hub

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

EBMT 2020

GvHD Types

In vitro and in vivo studies in mouse models elucidate the protective role of bile acids during intestinal aGvHD

In a preclinical study published in Haematologica, Eileen Haring and colleagues working under the supervision of GvHD steering committee...

Sep 17, 2020

Use of ruxolitinib in patients with severe COVID-19

A summary of the prospective observational study by the RUXO-COVID Study Group assessing response to ruxolitinib treatment in 34 patients with COVID-19-induced severe pulmonary disease.

Sep 15, 2020

How should antibiotics be administered in transplant patients to reduce GvHD?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Steering Committee member Arnon Nagler, Tel Aviv...

Sep 14, 2020

| EBMT 2020

New working definition of ruxolitinib-refractory acute GvHD

Mohamad Mohty, chair of the GvHD Hub Steering Committee, and colleagues published an article in Blood to define the patient population that can now be considered ruxolitinib-refractory, in...

Sep 10, 2020

Mohamad Mohty

" The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information. "

Featured Expert Opinion

How can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-host-disease?

Interview with Christine Spencer, Parker Institute of...

Cellular therapy

A comparison of GvHD characteristics in recipients of haploidentical vs matched unrelated donor transplantation

Sohl et al. evaluated the characteristics of a/cGvHD, including organ distribution,...

Sep 9, 2020

| cGvHD

Why is regulatory T-cell reconstitution important to prevent GvHD in allo-HSCT?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke...

Sep 4, 2020

| EBMT 2020

Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...

Sep 3, 2020

| EBMT 2020

Posttransplant cyclophosphamide for GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation

Analysis of two retrospective studies evaluating the impact of donor type on the outcome...

Aug 14, 2020

EHA 2020

Is arsenic trioxide effective in treating aGvHD? Results from an in vitro study

Xiao Liu and colleagues conducted a preclinical study to investigate the role of macrophage polarization in aGvHD and...

Jul 23, 2020

| EHA 2020

Can ruxolitinib be safely combined with regulatory T cells to enhance efficacy in treating cGVHD?

Virginia Escamilla Gómez and colleagues conducted a study to investigate whether adding Tregs to...

Jul 15, 2020

| EHA 2020

EHA 2020 | Phase III GRAVITAS-301 trial results on itacitinib plus corticosteroids for aGvHD

The results from the phase III GRAVITAS-301 trial that investigated the efficacy of the Janus kinase 1...

Jul 10, 2020

| EHA 2020

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg,...

Jun 18, 2020

| EHA 2020

Chronic graft-versus-host disease

A comparison of GvHD characteristics in recipients of haploidentical vs matched unrelated donor transplantation

Sohl et al. evaluated the characteristics of a/cGvHD, including organ distribution,...

Sep 9, 2020

| cGvHD

Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...

Sep 3, 2020

| EBMT 2020

ALWP/EBMT analysis |FLAMSA-based RIC vs MIC in young patients with R/R AML

Rodríguez-Arboli and colleagues recently published a comparative reassessment of FLAMSA-based RIC vs MAC in Biology of Blood...

Aug 17, 2020

Posttransplant cyclophosphamide for GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation

Analysis of two retrospective studies evaluating the impact of donor type on the outcome...

Aug 14, 2020

Most Viewed

Do pre-transplant depression and anxiety impact on the development of GvHD?

What are the latest advances in microbiota bioproducts?

How should antibiotics be administered in transplant patients to reduce GvHD?

Why is regulatory T-cell reconstitution important to prevent GvHD in allo-HSCT?

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Visit:

GvHD Types

In vitro and in vivo studies in mouse models elucidate the protective role of bile acids during intestinal aGvHD

Sep 17, 2020

Sep 15, 2020

Sep 14, 2020

| EBMT 2020

Sep 10, 2020

| SR GvHD

Mohamad Mohty

Cellular therapy

Sep 9, 2020

| cGvHD

Sep 4, 2020

| EBMT 2020

Sep 3, 2020

| EBMT 2020

Aug 14, 2020

EHA 2020

Jul 23, 2020

| EHA 2020

Jul 15, 2020

| EHA 2020

Jul 10, 2020

| EHA 2020

Jun 18, 2020

| EHA 2020

Most Read

Chronic graft-versus-host disease

Sep 9, 2020

| cGvHD

Sep 3, 2020

| EBMT 2020

Aug 17, 2020

Aug 14, 2020

Most Viewed